Literature DB >> 2426270

Domain-specific distribution of carbohydrates in human fibronectins and the transformation-dependent translocation of branched type 2 chain defined by monoclonal antibody C6.

E J Nichols, B A Fenderson, W G Carter, S Hakomori.   

Abstract

Fibronectins purified from human plasma (termed pFN), spent culture media of human fibroblasts WI38 (termed cFN), and SV40 virus-transformed WI38/VA13 cells (termed tFN) and their cleavage fragments were compared with respect to their binding activities to lectins and anti-carbohydrate antibodies reacting with chemically well-defined structures. The following findings were of particular interest. About 25-35% of cFN and tFN carried a binary sialosyl type 2 chain (NeuAc alpha 2----3/or 6Gal beta 1----4GlcNAc) linked beta 1----3/beta 1----6 to the galactose residue and defined by monoclonal antibody C6. This structure was not detected in pFN. In cFN, the C6-defined structure was localized within the gelatin-binding domain, whereas in tFN the same structure was absent from this domain but was located at the NH2-terminal region of the central domain. Other carbohydrate determinants, defined by Ricinus communis lectin and concanavalin A before and after sialidase treatment, showed essentially identical domain distribution patterns among cFN, tFN, and pFN and were all located at the gelatin-binding domain (44 kDa), its precursor (60 kDa), and the Cell/Hep-2 domain (155/145 kDa). Although both cFN and tFN were reactive with lentil lectin, pFN was not. Fibronectin from transformed cells (tFN) showed much greater reactivity than cFN and pFN with wheat germ lectin before sialidase treatment and showed enhanced reactivity with R. communis lectin and peanut lectin after sialidase treatment, indicating that tFN is more highly sialylated than cFN and pFN. All fibronectins examined were strongly reactive with monoclonal antibody AH8-28, which binds to Gal beta 1----3GalNAc residues, and this reactivity was localized to both the NH2-terminal half and COOH-terminal half of the S-cyanylation-cleaved fibronectin molecule.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2426270

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  The cellular form of human fibronectin as an adhesion target for the S fimbriae of meningitis-associated Escherichia coli.

Authors:  A Sarén; R Virkola; J Hacker; T K Korhonen
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 2.  The structural relationship of blood group-related oligosaccharides in human carcinoma to biological function: a perspective.

Authors:  V E Dube
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

3.  Molecular heterogeneity of gelatin-binding proteins from human seminal plasma.

Authors:  Maja M Kosanović; Miroslava M Janković
Journal:  Asian J Androl       Date:  2010-02-22       Impact factor: 3.285

4.  Changes in the secretion and glycosylation of fibronectin by human skin fibroblasts associated with tuberous sclerosis.

Authors:  H Uysal; J Saxton; F W Hemming
Journal:  Glycoconj J       Date:  1997-06       Impact factor: 2.916

5.  Carbohydrate heterogeneity of fibronectins. Synovial fluid fibronectin resembles the form secreted by cultured synoviocytes but differs from the plasma form.

Authors:  S Carsons; B B Lavietes; A Slomiany; H S Diamond; E Berkowitz
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

6.  Human keratinocytes express a new CD44 core protein (CD44E) as a heparan-sulfate intrinsic membrane proteoglycan with additional exons.

Authors:  T A Brown; T Bouchard; T St John; E Wayner; W G Carter
Journal:  J Cell Biol       Date:  1991-04       Impact factor: 10.539

7.  Site-Specific N- and O-Glycosylation Analysis of Human Plasma Fibronectin.

Authors:  Ding Liu; Shuaishuai Wang; Junping Zhang; Weidong Xiao; Carol H Miao; Barbara A Konkle; Xiu-Feng Wan; Lei Li
Journal:  Front Chem       Date:  2021-06-15       Impact factor: 5.221

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.